A modular and flexible ESC-based mouse model of pancreatic cancer

Genes and Development

Volumn 28, Issue 1, 2014, Pages 85-97

  Saborowski, Michael ^a   Saborowski, Anna ^a   Morris IV, John P ^a   Bosbach, Benedikt ^a   Dow, Lukas E ^a   Pelletier, Jerry ^b   Klimstra, David S ^a   Lowe, Scott W ^a,c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

Embryonic stem cell; Kras; Mouse model; Pancreas; Pancreatic cancer; RMCE

Indexed keywords

K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SHORT HAIRPIN RNA; TETRACYCLINE;

ALLELE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CELL CULTURE; CHIMERA; CONTROLLED STUDY; EMBRYONIC STEM CELL; FEMALE; FLUORESCENCE ANALYSIS; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENE SILENCING; GENETICALLY ENGINEERED MOUSE STRAIN; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; ONCOGENE C MYC; PANCREAS CANCER; PRIORITY JOURNAL; TRANSGENE; TUMOR SUPPRESSOR GENE;

EID: 84891711129     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.232082.113     Document Type: Article

References (46)

1. Aguirre A.J., Bardeesy N, Sinha M, Lopez L, Tuveson DA, Horner J, Redston MS, DePinho RA. 2003. Activated Kras and Ink4a/ Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 17: 3112-3126.
2. Ardito C.M., Gruner BM, Takeuchi KK, Lubeseder-Martellato C, Teichmann N., Mazur PK, Delgiorno KE, Carpenter ES, Halbrook CJ., Hall JC, et al. 2012. EGF receptor is required for KRAS-induced pancreatic tumorigenesis. Cancer Cell 22: 304-317.
3. Barcellos-Hoff M.H., Lyden D, Wang TC. 2013. The evolution of the cancer niche during multistage carcinogenesis. Nat Rev Cancer 13: 511-518.
4. Bardeesy N., Aguirre AJ, Chu GC, Cheng KH, Lopez LV, Hezel AF, Feng B, Brennan C, Weissleder R, Mahmood U, et al. 2006a. Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci 103: 5947-5952.
5. Bardeesy N., Cheng KH, Berger JH, Chu GC, Pahler J, Olson P, Hezel AF., Horner J, Lauwers GY, Hanahan D, et al. 2006b. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev 20: 3130-3146.
6. Beard C., Hochedlinger K, Plath K, Wutz A, Jaenisch R. 2006. Efficient method to generate single-copy transgenic mice by site-specific integration in embryonic stem cells. Genesis 44: 23-28.
7. Bonal C., Thorel F, Ait-Lounis A, Reith W, Trumpp A, Herrera PL. 2009. Pancreatic inactivation of c-Myc decreases acinar mass and transdifferentiates acinar cells into adipocytes in mice. Gastroenterology 136: 309-319. e9.
8. Bryja V., Bonilla S, Arenas E. 2006. Derivation of mouse embryonic stem cells. Nat Protoc 1: 2082-2087.
9. Cantley LC. 2002. The phosphoinositide 3-kinase pathway. Science 296: 1655-1657.
10. Chicas A., Wang X, Zhang C, McCurrach M, Zhao Z, Mert O, Dickins RA., Narita M, Zhang M, Lowe SW. 2010. Dissecting the unique role of the retinoblastoma tumor suppressor during cellular senescence. Cancer Cell 17: 376-387.
11. Dickins R.A., Hemann MT, Zilfou JT, Simpson DR, Ibarra I, Hannon G.J., Lowe SW. 2005. Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat Genet 37: 1289-1295.
12. Dickins R.A., McJunkin K, Hernando E, Premsrirut PK, Krizhanovsky V, Burgess DJ, Kim SY, Cordon-Cardo C, Zender L, Hannon GJ, et al. 2007. Tissue-specific and reversible RNA interference in transgenic mice. Nat Genet 39: 914-921.
13. Dow L.E., Lowe SW. 2012. Life in the fast lane: Mammalian disease models in the genomics era. Cell 148: 1099-1109.
14. Dow L.E., Premsrirut PK, Zuber J, Fellmann C, McJunkin K, Miething C., Park Y, Dickins RA, Hannon GJ, Lowe SW. 2012. A pipeline for the generation of shRNA transgenic mice. Nat Protoc 7: 374-393.
15. Eser S., Reiff N, Messer M, Seidler B, Gottschalk K, Dobler M, Hieber M., Arbeiter A, Klein S, Kong B, et al. 2013. Selective requirement of PI3K/PDK1 signaling for Kras oncogenedriven pancreatic cell plasticity and cancer. Cancer Cell 23: 406-420.
16. Fellmann C., Zuber J, McJunkin K, Chang K, Malone CD, Dickins RA., Xu Q, Hengartner MO, Elledge SJ, Hannon GJ, et al. 2011. Functional identification of optimized RNAi triggers using a massively parallel sensor assay. Mol Cell 41: 733-746.
17. Frese K.K., Tuveson DA. 2007. Maximizing mouse cancer models. Nat Rev Cancer 7: 645-658.
18. Gertsenstein M., Nutter LM, Reid T, Pereira M, Stanford WL, Rossant J., Nagy A. 2010. Efficient generation of germ line transmitting chimeras from C57BL/6N ES cells by aggregation with outbred host embryos. PLoS ONE 5: e11260.
19. Gittes GK. 2009. Developmental biology of the pancreas: A comprehensive review. Dev Biol 326: 4-35.
20. Hanahan D., Weinberg RA. 2011. Hallmarks of cancer: The next generation. Cell 144: 646-674.
21. Heiser P.W., Cano DA, Landsman L, Kim GE, Kench JG, Klimstra DS, Taketo MM, Biankin AV, Hebrok M. 2008. Stabilization of b-catenin induces pancreas tumor formation. Gastroenterology 135: 1288-1300.
22. Hemann M.T., Fridman JS, Zilfou JT, Hernando E, Paddison PJ, Cordon-Cardo C., Hannon GJ, Lowe SW. 2003. An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Nat Genet 33: 396-400.
23. Heyer J., Kwong LN, Lowe SW, Chin L. 2010. Non-germline genetically engineered mouse models for translational cancer research. Nat Rev Cancer 10: 470-480.
24. Hidalgo M. 2010. Pancreatic cancer. N Engl J Med 362: 1605-1617.
25. Hill R., Calvopina JH, Kim C, Wang Y, Dawson DW, Donahue TR, Dry S, Wu H. 2010. PTEN loss accelerates KrasG12Dinduced pancreatic cancer development. Cancer Res 70: 7114-7124.
26. Hingorani S.R., Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz M.A., Ross S, Conrads TP, Veenstra TD, Hitt BA, et al. 2003. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4: 437-450.
27. Hingorani S.R., Wang L, Multani AS, Combs C, Deramaudt TB, Hruban R.H., Rustgi AK, Chang S, Tuveson DA. 2005. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7: 469-483.
28. Huijbers I.J., Krimpenfort P, Berns A, Jonkers J. 2011. Rapid validation of cancer genes in chimeras derived from established genetically engineered mouse models. Bioessays 33: 701-710.
29. Jackson E.L., Willis N, Mercer K, Bronson RT, Crowley D, Montoya R., Jacks T, Tuveson DA. 2001. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 15: 3243-3248.
30. Jacobetz M.A., Chan DS, Neesse A, Bapiro TE, Cook N, Frese KK, Feig C., Nakagawa T, Caldwell ME, Zecchini HI, et al. 2013. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut 62: 112-120.
31. Jaiswal B.S., Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W., Kan Z, Dbouk HA, Peters BA, Waring P, et al. 2009. Somatic mutations in p85a promote tumorigenesis through class IA PI3K activation. Cancer Cell 16: 463-474.
32. Kawaguchi Y., Cooper B, Gannon M, Ray M, MacDonald RJ, Wright CV. 2002. The role of the transcriptional regulator Ptf1a in converting intestinal to pancreatic progenitors. Nat Genet 32: 128-134.
33. Mazur P.K., Einwachter H, Lee M, Sipos B, Nakhai H, Rad R, Zimber-Strobl U., Strobl LJ, Radtke F, Kloppel G, et al. 2010. Notch2 is required for progression of pancreatic intraepithelial neoplasia and development of pancreatic ductal adenocarcinoma. Proc Natl Acad Sci 107: 13438-13443.
34. McJunkin K., Mazurek A, Premsrirut PK, Zuber J, Dow LE, Simon J., Stillman B, Lowe SW. 2011. Reversible suppression of an essential gene in adult mice using transgenic RNA interference. Proc Natl Acad Sci 108: 7113-7118.
35. Nakhai H., Siveke JT, Mendoza-Torres L, Schmid RM. 2008. Conditional inactivation of Myc impairs development of the exocrine pancreas. Development 135: 3191-3196.
36. Olive K.P., Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, Crowley D., Jacks T. 2004. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119: 847-860.
37. Olive K.P., Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D., et al. 2009. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324: 1457-1461.
38. Premsrirut P.K., Dow LE, Kim SY, Camiolo M, Malone CD, Miething C., Scuoppo C, Zuber J, Dickins RA, Kogan SC, et al. 2011. A rapid and scalable system for studying gene function in mice using conditional RNA interference. Cell 145: 145-158.
39. Provenzano P.P., Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. 2012. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 21: 418-429.
40. Schonleben F., Qiu W, Ciau NT, Ho DJ, Li X, Allendorf JD, Remotti HE., Su GH. 2006. PIK3CA mutations in intraductal papillary mucinous neoplasm/carcinoma of the pancreas. Clin Cancer Res 12: 3851-3855.
41. Silva J.M., LiMZ, Chang K, GeW, Golding MC, Rickles RJ, Siolas D, Hu G, Paddison PJ, Schlabach MR, et al. 2005. Secondgeneration shRNA libraries covering the mouse and human genomes. Nat Genet 37: 1281-1288.
42. Sugiyama T., Rodriguez RT, McLean GW, Kim SK. 2007. Conserved markers of fetal pancreatic epithelium permit prospective isolation of islet progenitor cells by FACS. Proc Natl Acad Sci 104: 175-180.
43. Vogelstein B., Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. 2013. Cancer genome landscapes. Science 339: 1546-1558.
44. Ying H., Elpek KG, Vinjamoori A, Zimmerman SM, Chu GC, Yan H., Fletcher-Sananikone E, Zhang H, Liu Y, Wang W, et al. 2011. PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-kB-cytokine network. Cancer Discov 1: 158-169.
45. Zhou Y., Rideout WM 3rd, Zi T, Bressel A, Reddypalli S, Rancourt R., Woo JK, Horner JW, Chin L, Chiu MI, et al. 2010. Chimeric mouse tumor models reveal differences in pathway activation between ERBB family-and KRAS-dependent lung adenocarcinomas. Nat Biotechnol 28: 71-78.
46. Zuber J., McJunkin K, Fellmann C, Dow LE, Taylor MJ, Hannon GJ, Lowe SW. 2011. Toolkit for evaluating genes required for proliferation and survival using tetracycline-regulated RNAi. Nat Biotechnol 29: 79-83.